"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 5 | 4 | 9 |
| 2002 | 1 | 2 | 3 |
| 2003 | 2 | 4 | 6 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 1 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 2 | 5 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Ghoneum M, El-Gerbed MSA. Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses. Cancer Chemother Pharmacol. 2021 12; 88(6):961-971.
-
Berkovich R, Yakupova A, Eskenazi J, Carlson NG, Steinman L. Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
-
V?zquez-Otero I, Medina-Cintr?n N, Arroyo-?vila M, Gonz?lez-Sep?lveda L, Vil? LM. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. Lupus Sci Med. 2020 05; 7(1).
-
Mundisugih J, Fernando H, Bergin P, Hare J, Kaye D, Leet A, McGiffin D, Taylor AJ. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction. Prog Transplant. 2019 12; 29(4):327-334.
-
Lam L, Sathirareuangchai S, Oyama J, Devendra G, Hong R. Lymphocytic Myocarditis and Cardiogenic Shock in Hawai'i: A Case Series. Hawaii J Health Soc Welf. 2019 07; 78(7):223-229.
-
Avila-Ornelas J, Labat E, Alfonso G, Serrano C, Fiorito F. An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report. Mult Scler Relat Disord. 2019 Jun; 31:51-53.
-
Arnold DE, Seif AE, Jyonouchi S, Sullivan KE, Bunin NJ, Heimall JR. Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease. J Allergy Clin Immunol Pract. 2019 Mar; 7(3):1052-1054.e2.
-
Min S, Papaz T, Lafreniere-Roula M, Nalli N, Grasemann H, Schwartz SM, Kamath BM, Ng V, Parekh RS, Manlhiot C, Mital S. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation. Pediatr Transplant. 2018 11; 22(7):e13285.
-
Gago R, Shum LM, Vil? LM. Right upper quadrant abdominal pain as the initial presentation of polyarteritis nodosa. BMJ Case Rep. 2017 Feb 22; 2017.
-
Varela-Rosario N, P?rez-Berenguer JL, Vil? LM. Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis. BMJ Case Rep. 2016 Apr 05; 2016.